Explore Stanford technologies available for licensing:

Researchers in Prof. David Myung's laboratory have developed a bio-compatible, crosslinking gel that can be used for in situ repair of damaged cornea or as a three-dimensional scaffold for keratocyte-keratinocyte tissue culture.

Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.

Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.

Stanford researchers have designed and prototyped an inexpensive, compact and easy-to-use smartphone lens mount for the capture of high quality photographs and videos of the eye's front and back structures.

Stanford researchers led by Dr.

Researchers at Stanford have developed non-opiate methods for treating chronic pain and for retrograde transduction of neurons.

Stanford researchers have designed hydrogels that can be delivered to surgical sites in a patient's body for controlled and sustained release of bacteriophages to treat or prevent bacterial infections.

The potency of cancer immunotherapies for solid tumors are often diminished by inadequate metabolic reprogramming and resulting immune evasion in cancer.

Researchers in the Mackall lab at Stanford have developed an adoptive cell therapy modification that enhances anti-tumor activity by disrupting a specific group of genes.

Researchers at Stanford have developed a method using expressed genetic barcodes to enable simultaneous lineage tracing and single cell profiling. Intratumor heterogeneity fosters tumor evolution which is a key contributor to therapeutic failure and the lethality of cancer.

To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.

The Problem: Chronic pain is best treated with a 'whole-person' approach that include behavioral/psychological approaches to pain self-management.

Researchers at Stanford University have identified a small molecule tryptase inhibitor for treatment of severe allergies. Mast cells are a part of the innate and adaptive immune response. Mast Cell activation results in release of granules containing tryptases.

Exhausted T cells are T cells that become dysfunctional after a period of time and play a role in reduced efficacy of T cell targeted immunotherapies.